第一财经·2025-10-29 09:22Core Viewpoint - The article discusses the results of the 11th round of national drug centralized procurement in China, highlighting the competitive nature of the bidding process and the implications for pharmaceutical companies involved in the bidding [3][4]. Group 1: Procurement Results - The 11th round of centralized procurement included 55 types of drugs, with 445 companies participating and 453 products winning the proposed selection, resulting in a selection rate of nearly 60% [3][4]. - The average price difference for selected products has significantly narrowed compared to previous rounds, indicating a more competitive bidding environment [4][13]. Group 2: Competitive Dynamics - Companies generally adopted conservative pricing strategies, aiming for survival and market share rather than aggressive pricing, with only a few willing to bid higher [4][5]. - The most competitive products saw a high number of bidders, such as theophylline injection with 48 bidders, while some products experienced significant differentiation in bidding strategies [6][7]. Group 3: Case Studies - Yichang HEC Changjiang Pharmaceutical, known for its oseltamivir granules, unexpectedly lost its bid, which could lead to a loss of market share to the winning companies [7][8]. - Jiu Dian Pharmaceutical, previously the sole supplier of a pain relief product, won bids for multiple products at significantly lower prices than previous rounds, indicating a shift in market dynamics [10][11]. Group 4: Future Implications - The article suggests that the current procurement pricing mechanism may lead to short-term adjustments in revenue and profit margins for companies, emphasizing the need for strategic adaptations [12][13]. - The National Healthcare Security Administration aims to stabilize clinical supply and quality while preventing extreme price competition, indicating ongoing adjustments to procurement rules [13].